Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
60
SDZNY Quote, Financials, Valuation and Earnings
Last price:
$72.78
Seasonality move
:
1.21%
Day range:
$72.00 - $72.87
52-week range:
$35.61 - $76.84
Dividend yield:
1%
P/E ratio:
139.39x
P/S ratio:
2.97x
P/B ratio:
2.90x
Volume:
12.4K
Avg. volume:
26.6K
1-year change:
79.69%
Market cap:
$31.3B
Revenue:
$10.4B
EPS (TTM):
$0.53
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SDZNY
Sandoz Group AG
|
-- | -- | -- | -- | -- |
|
ACIU
AC Immune SA
|
$1.5M | -$0.19 | 18.61% | -6.92% | $9.01 |
|
ADXN
Addex Therapeutics Ltd.
|
$242.8K | -- | 2.35% | -- | $30.00 |
|
CRSP
CRISPR Therapeutics AG
|
$3.9M | -$1.23 | -89.16% | -180.62% | $81.33 |
|
ONC
BeOne Medicines Ltd.
|
$1.5B | $1.42 | 29.38% | -70.04% | $400.06 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SDZNY
Sandoz Group AG
|
$72.78 | -- | $31.3B | 139.39x | $0.73 | 1% | 2.97x |
|
ACIU
AC Immune SA
|
$3.14 | $9.01 | $315.9M | -- | $0.00 | 0% | 61.23x |
|
ADXN
Addex Therapeutics Ltd.
|
$7.72 | $30.00 | $9.5M | 0.77x | $0.00 | 0% | 35.31x |
|
CRSP
CRISPR Therapeutics AG
|
$52.44 | $81.33 | $5B | -- | $0.00 | 0% | 119.61x |
|
ONC
BeOne Medicines Ltd.
|
$303.81 | $400.06 | $33.6B | 584.59x | $0.00 | 0% | 6.79x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SDZNY
Sandoz Group AG
|
37.65% | 1.571 | -- | 0.63x |
|
ACIU
AC Immune SA
|
6.95% | 3.658 | 2.01% | 1.10x |
|
ADXN
Addex Therapeutics Ltd.
|
0.61% | 1.731 | 0.5% | 1.91x |
|
CRSP
CRISPR Therapeutics AG
|
9.92% | 2.726 | 3.47% | 16.13x |
|
ONC
BeOne Medicines Ltd.
|
31.57% | -0.083 | 5.05% | 2.09x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SDZNY
Sandoz Group AG
|
-- | -$3.6M | 1.73% | 2.69% | -13.72% | -- |
|
ACIU
AC Immune SA
|
-- | -$19.6M | -72.31% | -75.88% | -1671.93% | -$24.4M |
|
ADXN
Addex Therapeutics Ltd.
|
-- | -$869.9K | -73.49% | -73.84% | -1403.07% | -$687.4K |
|
CRSP
CRISPR Therapeutics AG
|
-$60.6M | -$132.1M | -23.42% | -26.17% | -14854.78% | -$84.7M |
|
ONC
BeOne Medicines Ltd.
|
$1.2B | $163.3M | 1.43% | 1.92% | 11.55% | $355.1M |
Sandoz Group AG vs. Competitors
-
Which has Higher Returns SDZNY or ACIU?
AC Immune SA has a net margin of -39.83% compared to Sandoz Group AG's net margin of -1688.87%. Sandoz Group AG's return on equity of 2.69% beat AC Immune SA's return on equity of -75.88%.
Company Gross Margin Earnings Per Share Invested Capital SDZNYSandoz Group AG-- -$0.28 $14.1B ACIUAC Immune SA-- -$0.20 $84.3M -
What do Analysts Say About SDZNY or ACIU?
Sandoz Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand AC Immune SA has an analysts' consensus of $9.01 which suggests that it could grow by 187.31%. Given that AC Immune SA has higher upside potential than Sandoz Group AG, analysts believe AC Immune SA is more attractive than Sandoz Group AG.
Company Buy Ratings Hold Ratings Sell Ratings SDZNYSandoz Group AG0 0 0 ACIUAC Immune SA4 0 0 -
Is SDZNY or ACIU More Risky?
Sandoz Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AC Immune SA has a beta of 1.623, suggesting its more volatile than the S&P 500 by 62.312%.
-
Which is a Better Dividend Stock SDZNY or ACIU?
Sandoz Group AG has a quarterly dividend of $0.73 per share corresponding to a yield of 1%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sandoz Group AG pays -21500.74% of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SDZNY or ACIU?
Sandoz Group AG quarterly revenues are $74.4M, which are larger than AC Immune SA quarterly revenues of $1.2M. Sandoz Group AG's net income of -$29.6M is lower than AC Immune SA's net income of -$19.8M. Notably, Sandoz Group AG's price-to-earnings ratio is 139.39x while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sandoz Group AG is 2.97x versus 61.23x for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SDZNYSandoz Group AG2.97x 139.39x $74.4M -$29.6M ACIUAC Immune SA61.23x -- $1.2M -$19.8M
-
Which has Higher Returns SDZNY or ADXN?
Addex Therapeutics Ltd. has a net margin of -39.83% compared to Sandoz Group AG's net margin of -3178.71%. Sandoz Group AG's return on equity of 2.69% beat Addex Therapeutics Ltd.'s return on equity of -73.84%.
Company Gross Margin Earnings Per Share Invested Capital SDZNYSandoz Group AG-- -$0.28 $14.1B ADXNAddex Therapeutics Ltd.-- -$2.10 $7.5M -
What do Analysts Say About SDZNY or ADXN?
Sandoz Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Addex Therapeutics Ltd. has an analysts' consensus of $30.00 which suggests that it could grow by 288.6%. Given that Addex Therapeutics Ltd. has higher upside potential than Sandoz Group AG, analysts believe Addex Therapeutics Ltd. is more attractive than Sandoz Group AG.
Company Buy Ratings Hold Ratings Sell Ratings SDZNYSandoz Group AG0 0 0 ADXNAddex Therapeutics Ltd.0 0 0 -
Is SDZNY or ADXN More Risky?
Sandoz Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Addex Therapeutics Ltd. has a beta of 1.487, suggesting its more volatile than the S&P 500 by 48.685%.
-
Which is a Better Dividend Stock SDZNY or ADXN?
Sandoz Group AG has a quarterly dividend of $0.73 per share corresponding to a yield of 1%. Addex Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sandoz Group AG pays -21500.74% of its earnings as a dividend. Addex Therapeutics Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SDZNY or ADXN?
Sandoz Group AG quarterly revenues are $74.4M, which are larger than Addex Therapeutics Ltd. quarterly revenues of $62K. Sandoz Group AG's net income of -$29.6M is lower than Addex Therapeutics Ltd.'s net income of -$2M. Notably, Sandoz Group AG's price-to-earnings ratio is 139.39x while Addex Therapeutics Ltd.'s PE ratio is 0.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sandoz Group AG is 2.97x versus 35.31x for Addex Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SDZNYSandoz Group AG2.97x 139.39x $74.4M -$29.6M ADXNAddex Therapeutics Ltd.35.31x 0.77x $62K -$2M
-
Which has Higher Returns SDZNY or CRSP?
CRISPR Therapeutics AG has a net margin of -39.83% compared to Sandoz Group AG's net margin of -11973.12%. Sandoz Group AG's return on equity of 2.69% beat CRISPR Therapeutics AG's return on equity of -26.17%.
Company Gross Margin Earnings Per Share Invested Capital SDZNYSandoz Group AG-- -$0.28 $14.1B CRSPCRISPR Therapeutics AG-6819.57% -$1.17 $2.1B -
What do Analysts Say About SDZNY or CRSP?
Sandoz Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.33 which suggests that it could grow by 55.1%. Given that CRISPR Therapeutics AG has higher upside potential than Sandoz Group AG, analysts believe CRISPR Therapeutics AG is more attractive than Sandoz Group AG.
Company Buy Ratings Hold Ratings Sell Ratings SDZNYSandoz Group AG0 0 0 CRSPCRISPR Therapeutics AG12 10 1 -
Is SDZNY or CRSP More Risky?
Sandoz Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.700, suggesting its more volatile than the S&P 500 by 69.984%.
-
Which is a Better Dividend Stock SDZNY or CRSP?
Sandoz Group AG has a quarterly dividend of $0.73 per share corresponding to a yield of 1%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sandoz Group AG pays -21500.74% of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SDZNY or CRSP?
Sandoz Group AG quarterly revenues are $74.4M, which are larger than CRISPR Therapeutics AG quarterly revenues of $889K. Sandoz Group AG's net income of -$29.6M is higher than CRISPR Therapeutics AG's net income of -$106.4M. Notably, Sandoz Group AG's price-to-earnings ratio is 139.39x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sandoz Group AG is 2.97x versus 119.61x for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SDZNYSandoz Group AG2.97x 139.39x $74.4M -$29.6M CRSPCRISPR Therapeutics AG119.61x -- $889K -$106.4M
-
Which has Higher Returns SDZNY or ONC?
BeOne Medicines Ltd. has a net margin of -39.83% compared to Sandoz Group AG's net margin of 8.84%. Sandoz Group AG's return on equity of 2.69% beat BeOne Medicines Ltd.'s return on equity of 1.92%.
Company Gross Margin Earnings Per Share Invested Capital SDZNYSandoz Group AG-- -$0.28 $14.1B ONCBeOne Medicines Ltd.83.86% $1.09 $6B -
What do Analysts Say About SDZNY or ONC?
Sandoz Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $400.06 which suggests that it could grow by 31.68%. Given that BeOne Medicines Ltd. has higher upside potential than Sandoz Group AG, analysts believe BeOne Medicines Ltd. is more attractive than Sandoz Group AG.
Company Buy Ratings Hold Ratings Sell Ratings SDZNYSandoz Group AG0 0 0 ONCBeOne Medicines Ltd.18 1 1 -
Is SDZNY or ONC More Risky?
Sandoz Group AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.467, suggesting its less volatile than the S&P 500 by 53.26%.
-
Which is a Better Dividend Stock SDZNY or ONC?
Sandoz Group AG has a quarterly dividend of $0.73 per share corresponding to a yield of 1%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sandoz Group AG pays -21500.74% of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SDZNY or ONC?
Sandoz Group AG quarterly revenues are $74.4M, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.4B. Sandoz Group AG's net income of -$29.6M is lower than BeOne Medicines Ltd.'s net income of $125M. Notably, Sandoz Group AG's price-to-earnings ratio is 139.39x while BeOne Medicines Ltd.'s PE ratio is 584.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sandoz Group AG is 2.97x versus 6.79x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SDZNYSandoz Group AG2.97x 139.39x $74.4M -$29.6M ONCBeOne Medicines Ltd.6.79x 584.59x $1.4B $125M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 1
Corcept Therapeutics, Inc. [CORT] is down 50.44% over the past day.
Buy
75
AXSM alert for Jan 1
Axsome Therapeutics, Inc. [AXSM] is up 22.82% over the past day.
Sell
50
NUTX alert for Jan 1
Nutex Health, Inc. [NUTX] is down 9.81% over the past day.
